| |
| |
|
| Insider
Information: |
Traversa Sergio |
| Relationship: |
Chief Executive Office... |
| City: |
Blue Bell |
| State: |
PA |
| |
|
| Insider
Summary: |
|
|
|
|
Companies Owned : |
2 |
|
| Direct
Shares |
247,024 |
|
|
Indirect Shares
|
0 |
|
|
| Direct
Value |
$756,522 |
|
|
|
Indirect Value
|
$0 |
|
|
| Total
Shares |
247,024 |
|
|
| Total
Value |
$756,522 |
|
|
|
|
|
|
|
|
Historical
Performance :
Based on 6 Month Return Percentages |
Buys
|
Sells
|
|
Total
Filings :
|
4
|
2
|
|
Stock
price went up :
|
1
|
0
|
| Stock
price went down : |
3
|
2
|
| |
|
|
|
Gain/Loss Ratio : |
0.0
|
-2.0
|
| Percentage
Gain/Loss : |
 -2.7%
|
-175.4%
|
| |
|
|
|
|
|
Holdings
:
| Menu |
Company Name |
Ticker |
Relation |
Direct Date |
Direct Shares |
Indirect Date |
Indirect Shares |
Total Value Sold  |
 |
Actinium Pharmaceuticals Inc |
ATNM |
Director |
2016-04-15 |
3,000 |
2013-08-08 |
0 |
Premium* |
|
|
Relmada Therapeutics, Inc. |
RLMD |
Chief Executive Office... |
2024-01-31 |
244,024 |
|
0 |
Premium* |
|
|
|
|
|
|
|
|
|
|
|
Records found :
37 |
Free Registration Required For Full Results. Limit: 25
|
 |
Download |
Page 2 of 2
|
| Ticker |
Company Name |
Relation |
Off-Dir-10% |
Trans. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
| RLMD |
Relmada Therapeutics, Inc... |
Chief Executive Officer |
• • – |
2022-06-30 |
4 |
OE |
$16.00 |
$256,192 |
D/D |
16,012 |
104,786 |
0 |
- |
|
| RLMD |
Relmada Therapeutics, Inc... |
Chief Executive Officer |
• • – |
2022-06-30 |
4 |
S |
$19.01 |
$306,301 |
D/D |
(16,012) |
88,774 |
0 |
% |
|
| RLMD |
Relmada Therapeutics, Inc... |
Chief Executive Officer |
• • – |
2022-07-01 |
4 |
OE |
$16.00 |
$220,080 |
D/D |
13,755 |
102,529 |
0 |
- |
|
| RLMD |
Relmada Therapeutics, Inc... |
Chief Executive Officer |
• • – |
2022-07-01 |
4 |
S |
$18.32 |
$253,276 |
D/D |
(13,755) |
88,774 |
0 |
% |
|
| RLMD |
Relmada Therapeutics, Inc... |
Chief Executive Officer |
• • – |
2022-12-08 |
4 |
B |
$2.10 |
$115,804 |
D/D |
55,250 |
144,024 |
2.81 |
% |
|
| RLMD |
Relmada Therapeutics, Inc... |
Chief Executive Officer |
• • – |
2024-01-29 |
4 |
B |
$3.71 |
$117,036 |
D/D |
31,541 |
175,565 |
2.81 |
% |
|
| RLMD |
Relmada Therapeutics, Inc... |
Chief Executive Officer |
• • – |
2024-01-30 |
4 |
B |
$3.90 |
$159,949 |
D/D |
40,999 |
216,564 |
2.81 |
% |
|
| RLMD |
Relmada Therapeutics, Inc... |
Chief Executive Officer |
• • – |
2024-01-31 |
4 |
B |
$4.00 |
$109,752 |
D/D |
27,460 |
244,024 |
2.81 |
% |
|
| RLMD |
Relmada Therapeutics, Inc... |
Chief Executive OfficerOfficer |
• • – |
2015-01-06 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
497,708 |
|
- |
|
| ATNM |
Actinium Pharmaceuticals ... |
Director |
– • – |
2016-04-14 |
4 |
B |
$2.02 |
$4,040 |
D/D |
2,000 |
2,000 |
2.31 |
- |
|
| ATNM |
Actinium Pharmaceuticals ... |
Director |
– • – |
2016-04-15 |
4 |
B |
$2.02 |
$2,020 |
D/D |
1,000 |
3,000 |
2.31 |
- |
|
| ATNM |
Actinium Pharmaceuticals ... |
Interim CFO |
• • – |
2013-08-08 |
4 |
A |
$3.60 |
$36,000 |
D/D |
10,000 |
0 |
0 |
- |
|
37 Records found
|
|
Page 2 of 2 |
| |
Free Registration Required For Full Results. Limit: 25
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Aquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
